CN113454123A - Lilrb3结合分子及其用途 - Google Patents

Lilrb3结合分子及其用途 Download PDF

Info

Publication number
CN113454123A
CN113454123A CN202080015060.4A CN202080015060A CN113454123A CN 113454123 A CN113454123 A CN 113454123A CN 202080015060 A CN202080015060 A CN 202080015060A CN 113454123 A CN113454123 A CN 113454123A
Authority
CN
China
Prior art keywords
seq
ser
thr
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080015060.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·布洛克斯
J·M·玛森
M·R·布雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN113454123A publication Critical patent/CN113454123A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080015060.4A 2019-01-18 2020-01-16 Lilrb3结合分子及其用途 Pending CN113454123A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962794064P 2019-01-18 2019-01-18
US62/794,064 2019-01-18
PCT/CA2020/050042 WO2020146946A1 (en) 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor

Publications (1)

Publication Number Publication Date
CN113454123A true CN113454123A (zh) 2021-09-28

Family

ID=71612981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080015060.4A Pending CN113454123A (zh) 2019-01-18 2020-01-16 Lilrb3结合分子及其用途

Country Status (14)

Country Link
US (1) US12404327B2 (https=)
EP (1) EP3911680A4 (https=)
JP (1) JP7631203B2 (https=)
KR (1) KR20210118116A (https=)
CN (1) CN113454123A (https=)
AU (1) AU2020209367A1 (https=)
BR (1) BR112021014102A2 (https=)
CA (1) CA3126295A1 (https=)
EA (1) EA202192008A1 (https=)
IL (1) IL284781A (https=)
MX (1) MX2021008507A (https=)
SG (1) SG11202107663UA (https=)
TW (1) TWI852980B (https=)
WO (1) WO2020146946A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925942A (zh) * 2022-06-08 2023-04-07 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130030156A1 (en) * 2010-01-20 2013-01-31 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CN107530402A (zh) * 2015-03-06 2018-01-02 德克萨斯大学体系董事会 抗lilrb抗体及其在检测和治疗癌症中的用途
CN107660150A (zh) * 2015-03-05 2018-02-02 Ab2生物股份有限公司 Il‑18结合蛋白(il‑18bp)和抗体在炎性疾病中
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
US20180201676A1 (en) * 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US9493561B2 (en) 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130030156A1 (en) * 2010-01-20 2013-01-31 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
US20180201676A1 (en) * 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
CN107660150A (zh) * 2015-03-05 2018-02-02 Ab2生物股份有限公司 Il‑18结合蛋白(il‑18bp)和抗体在炎性疾病中
CN107530402A (zh) * 2015-03-06 2018-01-02 德克萨斯大学体系董事会 抗lilrb抗体及其在检测和治疗癌症中的用途
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG J等: "Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers", J VIROL, vol. 84, no. 18, 14 July 2010 (2010-07-14), pages 9463 - 9471 *
许洁等: "白细胞免疫球蛋白样受体亚家族B生物学功能研究进展", 新乡医学院学报, vol. 35, no. 09, 3 September 2018 (2018-09-03), pages 835 - 839 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925942A (zh) * 2022-06-08 2023-04-07 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用

Also Published As

Publication number Publication date
KR20210118116A (ko) 2021-09-29
IL284781A (en) 2021-08-31
US12404327B2 (en) 2025-09-02
BR112021014102A2 (pt) 2021-09-21
WO2020146946A1 (en) 2020-07-23
CA3126295A1 (en) 2020-07-23
US20220089723A1 (en) 2022-03-24
MX2021008507A (es) 2021-09-21
JP7631203B2 (ja) 2025-02-18
TWI852980B (zh) 2024-08-21
EA202192008A1 (ru) 2021-10-21
EP3911680A1 (en) 2021-11-24
JP2022517809A (ja) 2022-03-10
EP3911680A4 (en) 2022-09-07
SG11202107663UA (en) 2021-08-30
TW202031685A (zh) 2020-09-01
AU2020209367A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7596298B2 (ja) 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
TWI852980B (zh) Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
US20220153834A1 (en) Tsg-6 antibodies and uses therefor
TWI857009B (zh) Ｆｃｍｒ結合分子及其用途
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210928